How Conditional FDA Approval of Credelio Quattro-CA1 Could Impact Elanco Animal Health (ELAN) Investors

Elanco Animal Health recently received conditional FDA approval for Credelio Quattro-CA1, the first companion animal treatment targeting New World screwworm infestations in dogs, reinforcing its ...

Elanco's Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approval for Treatment of New World ...

Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has received conditional approval from the U.S. Food and Drug Administration (FDA) for Credelio Quattro™-CA1 (lotilaner, moxidectin, ...

Elanco Animal Health: Elanco's Credelio Quattro-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approval for Treatment ...

Conditional Approval Marks Elanco's Third New World Screwworm Treatment Option for Companion Animals, Providing Multiple Treatment Solutions Prior to Fly Being Detected in the U.S. FDA's ...